Giles W. Story, PhD, from the University College London

Delay Discounting Offers No Predictive Value for MDD Relapse, With Giles Story, PhD

 who show greater impatience for delayed rewards are more likely to report residual depressive symptoms, but that behavioral trait does not predict relapse after stopping antidepressant therapy, according to new longitudinal data.

The findings suggest caution in using delay discounting as a clinical tool for guiding antidepressant discontinuation. Although this behavioral measure reflects known links between depression, impulsivity, and serotonergic function, investigators found it provided minimal predictive value in determining which patients are most likely to relapse after stopping medication.

“The bottom line is probably discounting is not going to be used like a lab test,” Giles W. Story, PhD, from the University College London, told 

Rather, clinicians use this study to guide conversations with patients about how depression may be associated with a focus on the present and challenges in planning for the future.

“We know avoidance is a big part of what maintains depression, and through that, people miss out on opportunities for longer-term rewards,” he added.

In a multi-site study led by Doron Elad, PhD, and Story, the study enrolled 97 patients with remitted MDD receiving antidepressant medication and 54 matched healthy controls across sites in Zurich and Berlin. Participants completed validated delay discounting tasks at baseline (MA1) and again after randomization to either antidepressant discontinuation or continuation, with 6 months of follow-up for relapse. Overall, 35% of patients relapsed during follow-up, while 65% remained well.

At baseline, patients with remitted MDD demonstrated significantly steeper delay discounting than controls (Cohen’s d = 0.34), indicating a greater tendency to favor immediate rewards. Delay discounting showed a modest association with depressive symptom severity, even when patients’ symptoms remained below the clinical threshold for relapse. For instance, patients were indifferent between receiving €66 immediately or €75 after a delay, whereas controls were indifferent at approximately €70.

Neither baseline discounting nor changes following antidepressant discontinuation predicted relapse during follow-up. Discontinuation led to only small increases in depressive symptoms, which may have been insufficient to shift discounting behavior.

“The effect that we saw after discontinuation of symptoms was quite small, so people's depressive symptoms did worsen slightly when they stopped medication, but these are people that already have quite low levels of symptoms, and they got just a tiny bit worse,” Story said. “It's probable that discount is probably just not sensitive enough to pick up that small change in symptoms.”

The results also challenge assumptions about behavioral markers as standalone predictors of relapse. Although residual symptoms predict relapse risk overall, they do not reliably predict whether stopping medication increases that risk.

Unexpectedly, higher baseline discounting was associated with greater symptom improvement over time.

“We thought that higher discounts at baseline might be associated with worsening of depression. The fact that we found the opposite strikes a bit of a note of caution,” Story said. “[It] could be a false positive occasionally…it's possible that there's another reason for…why discounting might be increasing depression. On the one hand… maybe that people are not willing to delay gratification, and that's actually part of something that maintains depression…On the other hand, it could be that becoming a bit more impulsive when you're depressed is actually adaptive, and it means that you can get a bit more immediate reward that boosts your mood a bit and carries you through.”

Elad D, Story GW, Berwian IM, Stephan KE, Walter H, Huys QJM. Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation. Mol Psychiatry. Published online January 8, 2026. 

Videos

Delay discounting links to residual depression symptoms but does not predict relapse after stopping antidepressant treatment in patients with remitted MDD.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Walter J. Liszewski, MD, is an associate professor of dermatology and cancer epidemiology at Northwestern University Feinberg School of Medicine.

Contact Dermatitis Updates for 2026, With Walter Liszewski, MD

, held at the Grand Wailea hotel, a session was presented titled ‘Contact Dermatitis Update 2026,’ during which the talk’s presenter highlighted the key challenges of managing a wide range of contact dermatitis issues.

This session was presented by Walter Liszewski, MD, associate professor of dermatology and cancer epidemiology at Northwestern University’s Feinberg School of Medicine. Liszewski spoke with the team at 

 about this session and what he feels are the most important elements of this talk.

“[In] patch testing, we have different Core Series,” Liszewski expressed. “These are [lists of] allergens that we set nationally for the US and Canada that will [include] the most common allergens, but they're not updated annually. What we start to see is that in between the periodic updates, which occur every 3 - 5 years, there may be new allergens that are all of a sudden becoming very relevant.”

Liszewski highlighted examples of these newly-relevant allergens, including benzisothiazolinone. He described this allergen as not included in the American Contact Dermatitis Series. Liszewski notes benzisothiazolinone’s structural similarity to methylisothiazolinone and methylchloroisothiazolinone.

However, it is used predominantly in hand soaps, dish soaps, and laundry detergents, so he urged clinicians to ask patients if their soap contains this ingredient. Later, Liszewski was also asked about the range of dermatitis dilemmas and what some of the most challenging or commonly mismanaged scenarios were, in his view.

“There are 2 major ones: The first is chronic hand eczema,” Liszewski explained. “...The second thing I talk about is chronic lip dermatitis or cheilitis; more often than not, it's not an allergy.”

To learn more about this topic and related information, view Liszewski’s full video interview posted above.

The quotes used in this video summary were edited for clarity.

Liszewski W. Contact Dermatitis Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Schalock PC, Dunnick CA, American Contact Dermatitis Society Core Allergen Series Committee, et al. American Contact Dermatitis Society Core Allergen Series: 2020 Update. Dermatitis. 2020 Sep-Oct;31(5):279-282. 

In this Maui Derm Hawaii 2026 interview, key takeaways on contact dermatitis treatment strategies are highlighted by Liszewski.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

January 2026 opened with major momentum across hepatology, particularly in metabolic and viral liver disease. The US Food and Drug Administration (FDA)’s decision to grant Breakthrough Therapy Designation to pemvidutide marked a significant milestone for metabolic dysfunction-associated steatohepatitis (MASH), reflecting growing confidence in dual agonist strategies supported by robust histologic and noninvasive data. In parallel, long-awaited phase 3 results for bepirovirsen signaled meaningful progress toward functional cure in chronic hepatitis B, with consistent efficacy across a broad, global patient population and especially strong responses in patients with lower baseline HBsAg levels.

Beyond late-stage trial readouts, January’s updates emphasized the evolving complexity of chronic liver disease care. Expert discussions highlighted the importance of addressing stigma and integrating multidisciplinary approaches in alcohol-associated liver disease, while advances in second-line therapies continued to reshape expectations for patients with primary biliary cholangitis (PBC). Rounding out the month, forward-looking perspectives on the MASH pipeline underscored a field transitioning from uncertainty to cautious optimism as multiple novel agents advance toward clinical reality.

Check out this January 2026 hepatology month in review for a recap of HCPLive’s coverage of the top hepatic news and research from the past few weeks:

Pemvidutide Gets Breakthrough Therapy Designation for MASH

On January 5, 2026, the FDA granted Breakthrough Therapy Designation to pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with MASH. The decision was supported by 24-week data from the IMPACT phase 2b trial demonstrating statistically significant MASH resolution without worsening of fibrosis, along with early and substantial improvements in liver fat and non-invasive tests of fibrosis and hepatic inflammation.

Bepirovirsen Meets Function Cure Endpoint in Phase 3 B-Well Trials for Hepatitis B

On January 7, 2026, GSK announced positive results from a pair of phase 3 trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide, for the treatment of chronic hepatitis B in > 1800 patients from 29 countries. Both trials met their primary endpoint and bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate. Of note, results were statistically significant across all ranked endpoints, including in patients with HBsAg <=1000 IU/ml where an even greater effect was demonstrated.

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Alcohol-associated liver disease remains a major and growing cause of liver-related morbidity and mortality, yet it is often approached through an oversimplified and stigmatized lens.

Misconceptions about who develops the disease, why it occurs, and how it should be treated continue to influence both patient engagement and clinical decision-making. With evolving understanding of the disease, Frances Lee, MD, describes increasing recognition that effective care extends beyond managing liver injury alone and requires a more nuanced, multidisciplinary approach.

Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments

The therapeutic landscape for PBC has undergone a meaningful transformation in recent years, offering new optimism for a disease long defined by limited treatment options. A. Sidney Barritt, MD, and Frances Lee, MD, review recent therapeutic progress, ongoing challenges, and what they foresee for the future of PBC management.

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

After years of setbacks and uncertainty, the therapeutic landscape for MASH has entered a decisive new phase. Once characterized by failed trials and a lack of approved therapies, the field has rapidly shifted toward cautious optimism, driven by regulatory clarity, advancing endpoints, and a deepening late-stage pipeline.

Mazen Noureddin, MD, MHSc, recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

HCPLive_Horizontal_VideoThumbnails Logan Briggs (2).png

Catch up on hepatic FDA news, expert insights on PBC and MASH developments, & more.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

5 Hepatology Headlines You Missed in January 2026

Susanne Brix Pedersen, professor at DTU Bioengineering

 Inside the Study Linking Infant Gut Bacteria to Lower Allergy Risk

Infants colonized early with specific bifidobacteria that produce aromatic lactate metabolites were significantly less likely to develop 

 and atopic dermatitis in childhood, according to new longitudinal data published in 

The findings add mechanistic clarity to the long-standing hypothesis that the infant gut microbiome helps shape immune tolerance during a narrow developmental window. In a prospective cohort of 147 children followed from birth to age 5, investigators identified a distinct microbiota–metabolite–immune axis associated with reduced food allergen–specific immunoglobulin E (IgE) and lower rates of eczema

The study, led by investigators at the Technical University of Denmark (DTU), tracked infants born between 2003 and 2005 in Sweden, with serial fecal sampling at 8 time points from birth through 5 years of age, alongside maternal samples, blood draws, and clinical data. Using genetic and metabolomic analyses, the team focused on a subset of bifidobacteria capable of converting aromatic amino acids into aromatic lactates. They wanted to see whether specific diseases could be prevented by having a certain microbiota early in life.

Infants with a high abundance of these bacteria, particularly in the first 6 months of life, had elevated gut levels of aromatic lactates and a markedly lower risk of food allergen–specific IgE through age 5. Infants with high levels of bifidobacteria that produced aromatic lactate metabolites had reduced atopic dermatitis at 2 years old. The protective association was mediated by 4-hydroxy-phenyllactate (4-OH-PLA), a bacterial metabolite that selectively inhibited IgE production in ex vivo human immune cell cultures without affecting IgG.

“Even though that we see that [4-hydroxy-phenyllactate] can reduce IGE production…in human immune cell populations, we don't know exactly why,” said investigator Susanne Brix Pedersen, professor at DTU Bioengineering, in an interview with 

. “We know that humans, but not other animals except chimpanzees…have a specific receptor that can bind to these aromatic lactates, but we haven't been able to see that it's mediated via these receptors ye, so it might be other routes for interaction with the immune cells that has just not been discovered yet, but we do see this reduction.”

Early-life exposures strongly influenced whether infants acquired these bacteria. Vaginal delivery, exclusive breastfeeding during the first two months, and exposure to older siblings were all associated with higher colonization, with vaginally delivered infants up to 14 times more likely to acquire the strains from their mothers.

If confirmed, the findings could inform new preventive strategies—ranging from targeted probiotics to metabolite-enriched formulas—aimed at reducing the growing global burden of childhood allergies and asthma. Pedersen emphasized that this current data does not yet establish causality.

“There's no causal link at this moment,” Pederson said. “As I see it, we have this prospective study where we see associations, but we don't have any studies that have been designed to actually look at the causal interaction at this moment, but we are undertaking a bigger study in 1000 Danish infants, where we are trying to…investigate this in detail.”

Myers PN, Dehli RK, Mie A, et al. Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization. 

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Early-Life Bifidobacteria Linked to Lower Food Allergy Risk, With Susanne Brix Pedersen

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

January 2026 brought a wave of clinically meaningful updates across 

, spanning new clinical practice guidelines, regulatory approvals, and late-stage pipeline momentum in both malignant and nonmalignant disease. Organizations including the 

 and Kidney Disease: Improving Global Outcomes (KDIGO) released updated guidance aimed at improving diagnostic accuracy and supportive care, while the 

expanded treatment options for rare bleeding and thrombotic disorders.

Notable developments this month included new ASH guidelines to support earlier diagnosis of AL amyloidosis, FDA approvals expanding access to therapies for acquired fibrinogen deficiency and pediatric acquired thrombotic thrombocytopenic purpura, and the submission of a New Drug Application (NDA) for rusfertide in polycythemia vera. In addition, ASH leadership highlighted ongoing efforts to address funding facing the hematology community. Together, these updates reflect continued progress in precision diagnostics, rare disease management, and the future sustainability of hematology research and care.

Read below to catch up on the 6 hematology headlines you missed in January 2026. 

ASH Addresses Funding, Career Development Gaps in Hematology, With President Robert Negrin, MD

HCPLive spoke with Robert Negrin, MD, the newly elected president of ASH, about the society’s initiatives to sustain hematology research, support early-career development, and address global challenges in clinical hematology.

 Looking Ahead to ASH’s 68th Meeting, With President Robert Negrin, MD

KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease

The 2026 KDIGO guideline update for the management of anemia in chronic kidney disease expands upon the prior 2012 guidance, with updated recommendations and practice points related to iron management, red blood cell (RBC) transfusions, and emerging therapies. The guideline incorporates new evidence intended to support individualized anemia management across the spectrum of CKD care.

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

, new clinical practice guidelines from ASH outline best practices to support clinicians in recognizing and diagnosing AL amyloidosis, a disease frequently missed or diagnosed late due to its heterogeneous presentation.

The panelists recommend blood and urine testing, including serum immunofixation, urine immunofixation, and serum free light chain assays, when clinical suspicion for AL amyloidosis exists. To confirm diagnosis, the panel supports the use of surrogate biopsies through combined bone marrow biopsy and abdominal fat pad sampling in most cases, while recognizing that target organ biopsies may be appropriate in select clinical scenarios.

FDA Approves Caplacizuman-yhdp (Cavlivi) as First Pediatric aTTP Therapy

On January 5, 2026, the FDA approved caplacizumab-yhdp (Cablivi; Sanofi) for injection to treat pediatric patients aged ≥12 years with acquired thrombotic thrombocytopenic purpura, in combination with plasma exchange and immunosuppressive therapy. The decision builds upon caplacizumab’s initial 2019 approval for adults with aTTP.

The approval was supported by efficacy data from a retrospective chart review of 30 patients aged 2–18 years, in which 80% achieved clinical remission. Notably, the decision makes caplacizumab the first FDA-approved therapy for pediatric aTTP.

FDA Approves 2-Gram Presentation of Fibryga for Acquired Fibrinogen Deficiency

On January 7, 2026, the FDA approved a 2-gram presentation of fibrinogen (human) lyophilized powder for reconstitution (Fibryga) for fibrinogen replacement in patients with acquired fibrinogen deficiency. Fibryga is the first and only virus-inactivated, human plasma–derived fibrinogen concentrate approved for this indication in the US.

Takeda and Protagonist Announce Submission of Rusfertide NDA for Polycythemia Vera

Takeda and Protagonist Therapeutics announced the submission of a new drug application to the FDA for rusfertide to treat adult patients with polycythemia vera. The submission is based on a positive 32-week primary analysis and 52-week results from VERIFY, a phase 3 study evaluating rusfertide in combination with standard of care. The ongoing trial will follow patients for up to 124 weeks.

Articles

January 2026 hematology advances spanned practice-changing guidelines and regulatory milestones across malignant and nonmalignant disease. KDIGO updated anemia-in-CKD recommendations with expanded guidance on iron therapy, transfusion strategy, and emerging agents to enable more individualized care. ASH issued new diagnostic guidance for AL amyloidosis emphasizing early recognition and standardized lab evaluation, with surrogate biopsy pathways for confirmation. FDA actions broadened access in rare disorders, including caplacizumab for pediatric aTTP and a higher-dose Fibryga presentation for acquired fibrinogen deficiency. Rusfertide’s NDA in polycythemia vera signaled late-stage pipeline momentum amid ongoing funding concerns.

January 2026 Hematology Month in Review highlights new ASH and KDIGO guidelines, FDA approvals, and pipeline progress in rare blood disorders.


Hematology

6 Hematology Headlines You Missed in January 2026 

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA approvals, priority review decisions, and new data on treatment response and mechanisms highlight a month of progress in MDD and ADHD.

6 Psychiatry Headlines You Missed in January 2026

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing Psoriasis Treatment Updates for 2026, With Eingun James Song, MD

Paul Sorajja, MD, is the associate director of the Banner – University Medicine Heart Institute and professor of medicine at the University of Arizona. 

Sorajja describes his team’s operation to implant the ring via a novel trans-septal system, effectively avoiding the need to stop the heart in MR treatment.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Structural Heart Disease

First-in-America Implantation of AMEND Annuloplasty Ring in Mitral Regurgitation, With Paul Sorajja, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

Risankizumab Compared to Icotrokinra in Adult Patients with Psoriasis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonary Fibrosis

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

7 Pulmonology Headlines You Missed in January 2026

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

7 Allergy Headlines You Missed in January 2026

Eliezer Katz, MD, is the chief medical officer at Eledon Pharmaceuticals. 

Eliezer Katz, MD, says investigational anti-CD40L therapy tegoprubart shows promise as a non-calcineurin inhibitor option for adult de novo kidney transplant patients

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients,  With Eliezer Katz, MD

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

FDA News

Anaphylm Remains Promising for Anaphylaxis Despite FDA CRL, With David Golden, MD

Ahmad Anouti, MD, is a pediatric resident at the University of Texas Southwestern in the Physician Scientist Training Program.

Anouti describes clinical uncertainties regarding signs of cholestatic liver disease, like jaundice, in patients with skin of color, and how this may impact transplant outcomes.

Diagnostic Challenges and Transplant Outcomes in Pediatric Cholestatic Liver Disease, With Ahmad Anouti, MD

AbbVie’s upadacitinib (Rinvoq) has had its regulatory applications submitted to the FDA and the EMA, with the drug being indicated for adults and adolescents with vitiligo.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Latest News

Delay Discounting Offers No Predictive Value for MDD Relapse, With Giles Story, PhD

Contact Dermatitis Updates for 2026, With Walter Liszewski, MD

5 Hepatology Headlines You Missed in January 2026

Early-Life Bifidobacteria Linked to Lower Food Allergy Risk, With Susanne Brix Pedersen

6 Hematology Headlines You Missed in January 2026